IP Library Granted Patent US 11,795,320
Granted Patent B2
US 11,795,320 · App. 17/022,398 · Granted Oct 24, 2023

Grafted polymer and use thereof

Inventors: James Anthony DiBella, Jr. (Macedon, NY); Alok Kumar Awasthi (Pittsford, NY); Jade J. Russell (Perry, NY); Mark R. Mis (Rush, NY); James Hauenstein (Williamson, NY); Mark Fornalik (Webster, NY); Andrew J. Hoteling (Ontario, NY); Shawn M. Conlon (Webster, NY); Kaushlendra Kumar (Bangalore, IN)
Assignee: BAUSCH + LOMB IRELAND LIMITED
C08L51/02A61L12/086A61L26/0023C08K5/053G02B1/043C08L71/02C08L2201/08C08L2312/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,795,320
App. No.
17/022,398
Granted
Oct 24, 2023
Kind
B2
Abstract

A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

Claims (33)

1. A grafted glycosaminoglycan polymer which is a reaction product of (a) a glycosaminoglycan having a polymer backbone containing reactive functionalities, wherein a given one of the reactive functionalities is an epoxide reactive functionality; (b) a polyol and (c) an epoxyalcohol; wherein the epoxide reactive functionality of the polymer backbone forms one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the epoxide reactive functionality of the polymer backbone of the glycosaminoglycan.

2. The grafted glycosaminoglycan polymer according to claim 1 , wherein the glycosaminoglycan is selected from the group consisting of chondroitin, chondroitin sulfate, dermatan, dermatan sulfate, heparin, heparan sulfate, heparosan, hyaluronan, hyaluronic acid, sucrose, lactulose, lactose, maltose, trehalose, cellobiose, mannobiose, chitobiose, chitosan and cellulose.

3. An aqueous ophthalmic composition comprising one or more of the grafted glycosaminoglycan polymers according to claim 1 , wherein the aqueous ophthalmic composition has an osmolality in a range from about 200 mOsmol/kg to about 500 mOsmol/kg.

4. The aqueous ophthalmic composition according to claim 3 , in the form of an eye care or a contact lens care product selected from the group consisting of eye drops, a contact lens preservative solution, a contact lens cleaning solution, and a contact lens multi-purpose solution.

5. The aqueous ophthalmic composition according to claim 3 , in the form of a multi-purpose solution or rewetting drops.

6. The grafted glycosaminoglycan polymer according to claim 1 , wherein the reactive functionalities of the glycosaminoglycan comprises at least one carboxylic acid reactive functionality.

7. The grafted glycosaminoglycan polymer according to claim 6 , wherein the glycosaminoglycan comprising the at least one carboxylic acid reactive functionality is hyaluronic acid or a salt thereof.

8. The grafted glycosaminoglycan polymer according to claim 1 , wherein the reaction product has a degree of grafting of the number of side chains in the polymer backbone containing the polyalkylene glycol-containing residue ranging from about 5 to 100%.

9. The grafted glycosaminoglycan polymer according to claim 1 , wherein the epoxide reactive functionality of the polymer backbone of the glycosaminoglycan is derived from activating the glycosaminoglycan in a solution comprising an activator comprising one or more epoxyamines in the presence of one or more catalysts.

10. The grafted glycosaminoglycan polymer according to claim 9 , wherein the one or more catalysts comprise a carbodiimide catalyst system.

11. The grafted glycosaminoglycan polymer according to claim 10 , wherein the carbodiimide catalyst system comprises 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and one of N-hydroxysuccinimide, sulfo-N-hydroxysuccinimide or hydroxybenzotriazole.

12. A grafted glycosaminoglycan polymer which is a reaction product of (a) a glycosaminoglycan having a polymer backbone containing reactive functionalities; and (b) a polymer comprising polyalkylene glycol chains and at least one reactive end group complementary to at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan; wherein the at least one reactive end group of the polymer forms one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan, wherein the reaction product is derived from (i) activating the glycosaminoglycan in a solution comprising one or more catalysts with an activator comprising one or more epoxyamines; and (ii) grafting the one or more side chains comprising the polyalkylene glycol-containing residue onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan by sequentially or simultaneously adding a polyol and an epoxyalcohol to the activated glycosaminoglycan.

13. The grafted glycosaminoglycan polymer according to claim 12 , wherein the one or more epoxyamines include both at least one amine moiety and at least one epoxide moiety.

14. The grafted glycosaminoglycan polymer according to claim 12 , wherein the one or more epoxyamines comprise a monoepoxyamine, and a polyepoxyamine.

15. The grafted glycosaminoglycan polymer according to claim 12 , wherein the one or more epoxyamines include an epoxyethylamine, an epoxypropylamine, an epoxybutylamine, and an epoxyamyl amine.

16. The grafted glycosaminoglycan polymer according to claim 12 , wherein the polyol and the epoxyalcohol form in-situ the polymer comprising polyalkylene glycol chains and at least one reactive end group.

17. The grafted glycosaminoglycan polymer according to claim 12 , wherein the polyol is a diol, and the epoxyalcohol is a monoepoxyalcohol compound or a polyepoxyalcohol.

18. The grafted glycosaminoglycan polymer according to claim 12 , wherein the one or more catalysts comprise a carbodiimide catalyst system.

19. The grafted glycosaminoglycan polymer according to claim 18 , wherein the carbodiimide catalyst system comprises 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and one of N-hydroxysuccinimide, sulfo-N-hydroxysuccinimide or hydroxybenzotriazole.

20. The grafted glycosaminoglycan polymer according to claim 1 , wherein the glycosaminoglycan is an unmodified glycosaminoglycan.

21. An aqueous ophthalmic composition comprising one or more of the grafted glycosaminoglycan polymers according to claim 6 , wherein the aqueous ophthalmic composition has an osmolality in a range from about 200 mOsmol/kg to about 500 mOsmol/kg.

22. The aqueous ophthalmic composition according to claim 21 , in the form of an eye care or a contact lens care product selected from the group consisting of eye drops, a contact lens preservative solution, a contact lens cleaning solution, and a contact lens multi-purpose solution.

23. The aqueous ophthalmic composition according to claim 21 , in the form of a multi-purpose solution or rewetting drops.

24. An aqueous ophthalmic composition comprising one or more of the grafted glycosaminoglycan polymers according to claim 9 , wherein the aqueous ophthalmic composition has an osmolality in a range from about 200 mOsmol/kg to about 500 mOsmol/kg.

25. The aqueous ophthalmic composition according to claim 24 , in the form of an eye care or a contact lens care product selected from the group consisting of eye drops, a contact lens preservative solution, a contact lens cleaning solution, and a contact lens multi-purpose solution.

26. The aqueous ophthalmic composition according to claim 24 , in the form of a multi-purpose solution or rewetting drops.

27. An aqueous ophthalmic composition comprising a grafted glycosaminoglycan polymer which is a reaction product of (a) a glycosaminoglycan having a polymer backbone containing reactive functionalities; and (b) a polymer comprising polyalkylene glycol chains and at least one reactive end group complementary to at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan, wherein the at least one reactive end group of the polymer forms one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan, wherein the reaction product is derived from (i) activating the glycosaminoglycan in a solution comprising one or more catalysts with an activator comprising one or more epoxyamines; and (ii) grafting the one or more side chains comprising the polyalkylene glycol-containing residue onto the at least one of the reactive functionalities of the polymer backbone of the glycosaminoglycan by sequentially or simultaneously adding a polyol and an epoxyalcohol to the activated glycosaminoglycan;

wherein the aqueous ophthalmic composition has an osmolality in a range from about 200 mOsmol/kg to about 500 mOsmol/kg.

28. The aqueous ophthalmic composition according to claim 27 , in the form of an eye care or a contact lens care product selected from the group consisting of eye drops, a contact lens preservative solution, a contact lens cleaning solution, and a contact lens multi-purpose solution.

29. The aqueous ophthalmic composition according to claim 27 , wherein the one or more epoxyamines include an epoxyethylamine, an epoxypropylamine, an epoxybutylamine, and an epoxyamyl amine.

30. The aqueous ophthalmic composition according to claim 27 , wherein the polyol and the epoxyalcohol form in-situ the polymer comprising polyalkylene glycol chains and at least one reactive end group.

31. The aqueous ophthalmic composition according to claim 27 , wherein the polyol is a diol, and the epoxyalcohol is a monoepoxyalcohol compound or a polyepoxyalcohol.

32. The aqueous ophthalmic composition according to claim 27 , wherein the one or more catalysts comprise a carbodiimide catalyst system.

Assignments (19)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (061391/0172) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072486/0769 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED; BAUSCH + LOMB CORPORATION
Reel/Frame 067131/0651 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056304/0581) Recorded Apr 17, 2024
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 067131/0629 →
SECURITY INTEREST Recorded Feb 12, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066552/0041 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 060346/0705) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061848/0790 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 056304/0556) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061776/0619 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 8, 2022
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 061391/0172 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2022
From: BAUSCH HEALTH IRELAND LIMITED
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 058755/0636 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND INVENTOR'S NAME PREVIOUSLY RECORDED AT REEL: 053787 FRAME: 0569. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 21, 2021
From: DIBELLA, JAMES ANTHONY, JR; AWASTHI, ALOK K.; RUSSELL, JADE J.; MIS, MARK R.; HAUENSTEIN, JAMES; FORNALIK, MARK; HOTELING, ANDREW J.; CONLON, SHAWN M.
To: BAUSCH HEALTH US, LLC
Reel/Frame 057701/0071 →
SECURITY INTEREST Recorded May 20, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH + LOMB IRELAND LIMITED; BAUSCH HEALTH US, LLC; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056304/0581 →
SECURITY INTEREST Recorded May 20, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH + LOMB IRELAND LIMITED; BAUSCH HEALTH US, LLC; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 056304/0556 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2020
From: DIBELLA, JAMES ANTHONY; ALWASTHI, ALOK K.; RUSSELL, JADE J; MIS, MARK R.; HAUENSTEIN, JAMES; FORNALIK, MARK; HOTELING, ANDREW J.; CONLON, SHAWN M.
To: BAUSCH HEALTH US, LLC
Reel/Frame 053787/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2020
From: KUMAR, KAUSHLENDRA
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 053787/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2020
From: BAUSCH HEALTH US, LLC
To: BAUSCH HEALTH IRELAND LIMITED
Reel/Frame 053787/0588 →